Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) EPS (Basic) (2024 - 2026)

Evommune (EVMN) reported EPS (Basic) of -$0.64 for Q1 2026, up 93.25% year-over-year from -$0.33 in Q1 2025, and down 104.23% on a QoQ basis from $15.14 in Q4 2025.

Evommune (EVMN) has 3 years of EPS (Basic) data on file, last reported at -$0.64 in Q1 2026.

  • Quarterly EPS (Basic) rose 93.25% year-over-year to -$0.64 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.05 (changed N/A YoY) and the FY2025 annual result came in at -$11.22, up 75.23% from the prior year.
  • EPS (Basic) retreated to -$0.64 in Q1 2026 per EVMN's latest filing, from $15.14 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $15.14 in Q4 2025 and bottomed at -$14.6 in Q4 2024.
  • The 3-year median for EPS (Basic) is -$8.78 (2025), against an average of -$4.69.
  • Peak annual rise in EPS (Basic) reached 203.7% in 2025, while the deepest fall reached 22.92% in 2025.
  • Tracing EVMN's EPS (Basic) over 3 years: stood at -$14.6 in 2024, then jumped by 203.7% to $15.14 in 2025, then tumbled by 104.23% to -$0.64 in 2026.
  • Per Business Quant, the three latest EVMN EPS (Basic) figures stand at -$0.64 (Q1 2026), $15.14 (Q4 2025), and -$8.07 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 3.06
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.06
7 Evaxion A 62.56 Bn 62.54 Bn - 0.00
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.99
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.55
10 Evommune 744.11 Mn 532.65 Mn - -0.64

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.64
Dec 31, 2025 15.14
Sep 30, 2025 -8.07
Mar 31, 2025 -9.48
Dec 31, 2024 -14.60
Sep 30, 2024 -10.47